Jami Rubin

Jami Rubin Recent News

This Wasn't A Great ESMO For Bristol-Myers Squibb, But 2017 Could Be A Much Better Year
Goldman On The Drug Price Increase Debate: Separating The Winners From The Losers
Lilly Is Entering A Period Of Accelerated Growth; Goldman Upgrades Stock To Buy
Abbvie Is One Of The Most 'Dislocated Names' In Pharma
Greater EpiPen Access, Price Transparency Should Dampen Concern; Goldman Maintains Mylan's Conviction Buy Status
Goldman Sachs Talks Pfizer's Acquisition Deal Of Medivation
Goldman Sachs Sees 'Limited Upside' In Teva Regardless Of Acquisition Results
Goldman Confident In Merck's Keytruda
Goldman Removes Mylan From Its Conviction List
Allergan Is Primed For Growth, Goldman Sees 27% Upside Potential
Goldman Downgrades Zoetis, Sees Limited Upside
Bristol-Myers Squibb Target, Estimates Under Review At Goldman Sachs
Goldman Selling Perrigo, Prefers Mylan And Teva
Goldman Reinstates Coverage On Pfizer And Allergan Following Failed Merger
Goldman Upgrades Johnson & Johnson, Removes From America's Sell List
Johnson & Johnson Sales Fall: What The Street Is Saying Now
UPDATE: Goldman Sachs Upgrades Teva Pharmaceutical Industries
UPDATE: Goldman Sachs Downgrades Eli Lilly & Company on Relative Lack of Differentiation in Pipeline
UPDATE: Goldman Sachs Upgrades Johnson & Johnson Based on Solid Pharma Business
UPDATE: Goldman Sachs Raises PT on Mylan on Increased Confidence in Key Revenue/Earnings Drivers
UPDATE: Goldman Sachs Upgrades Perrigo on Multiple Positive Factors
UPDATE: Goldman Sachs Downgrades Teva Pharmaceuticals on Brand Focus Taking Time
UPDATE: Goldman Sachs Upgrades Forest Laboratories on Increased Potential for Strategic Options

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga

© 2024 Benzinga | All Rights Reserved